Excision repair cross complementation group 1 is a chemotherapy-tolerating gene in cisplatin-based treatment for non-small cell lung cancer

International Journal of Oncology

Volumn 46, Issue 2, 2015, Pages 809-817

  Wang, Shoufeng ^a   Pan, Hong ^a   Liu, Desen ^a   Mao, Naiquan ^a   Zuo, Chuantian ^a   Li, Li ^a   Xie, Tong ^a   Huang, Dingming ^a   Huang, Yaoyuan ^a   Pan, Qi ^a   Yang, Li ^a   Wu, Junwei ^a  

^a GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

Cisplatin resistance; Excision repair cross complementation group 1; Non small cell lung cancer

Indexed keywords

CELL MEMBRANE PROTEIN; CISPLATIN; DOXORUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN; SMALL INTERFERING RNA; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

A549 CELL LINE; ARTICLE; BIOLOGICAL FUNCTIONS; CANCER CHEMOTHERAPY; CANCER THERAPY; CELL CYCLE; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CLINICAL EVALUATION; COLONY FORMATION; CYTOTOXICITY; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOLECULAR CLONING; MTT ASSAY; NON SMALL CELL LUNG CANCER; PROTEIN EXPRESSION; SENSITIVITY ANALYSIS; TREATMENT RESPONSE; TUMOR INVASION; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; PATHOLOGY; PROGNOSIS; TUMOR CELL LINE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM INVASIVENESS; PROGNOSIS; RNA, SMALL INTERFERING;

EID: 84918526741     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2784     Document Type: Article

References (37)

1. Le Chevalier T: Adjuvant chemotherapy for resectable non-smallcell lung cancer: where is it going? Ann Oncol 21 (Suppl 7): vii196-vii198, 2010.
2. Azzoli CG, Park BJ, Pao W, Zakowski M and Kris MG: Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer: a time for excitement and equipoise. J Thorac Oncol 3: 84-93, 2008.
3. Dziadziuszko R and Hirsch FR: Advances in genomic and proteomic studies of non-small-cell lung cancer: clinical and translational research perspective. Clin Lung Cancer 9: 78-84, 2008.
4. Taillade L, Penault-Llorca F, Boulet T, et al: Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small cell lung cancer. Ann Oncol 18: 1043-1050, 2007.
5. Toschi L and Cappuzzo F: Impact of biomarkers on non-small cell lung cancer treatment. Target Oncol 5: 5-17, 2010.
6. Bowden NA: Nucleotide excision repair: why is it not used to predict response to platinum-based chemotherapy? Cancer Lett 346: 163-171, 2014.
7. Simon GR, Ismail-Khan R and Bepler G: Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 39: 1318-1328, 2007.
8. Rosell R, Lord RV, Taron M and Reguart N: DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38: 217-227, 2002.
9. Friboulet L, Barrios-Gonzales D, Commo F, et al: Molecular characteristics of ERCC1-negative versus ERCC1-positive tumors in resected NSCLC. Clin Cancer Res 17: 5562-5572, 2011.
10. Bepler G: Pharmacogenomics: a reality or still a promise? Lung Cancer 54 (Suppl 2): S3-S7, 2006.
11. Custodio A, Mendez M and Provencio M: Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat Rev 38: 36-53, 2012.
12. Stewart DJ: Tumor and host factors that may limit efficacy of chemotherapy in non-small cell and small cell lung cancer. Crit Rev Oncol Hematol 75: 173-234, 2010.
13. Gossage L and Madhusudan S: Current status of excision repair cross complementing-group 1 (ERCC1) in cancer. Cancer Treat Rev 33: 565-577, 2007.
14. Rosell R, Vergnenegre A, Liu B, et al: Biomarkers in lung oncology. Pulm Pharmacol Ther 23: 508-514, 2010.
15. Chen J, Emara N, Solomides C, Parekh H and Simpkins H: Resistance to platinum-based chemotherapy in lung cancer cell lines. Cancer Chemother Pharmacol 66: 1103-1111, 2010.
16. Rosell R, Cobo M, Isla D, Camps C and Massuti B: Pharmacogenomics and gemcitabine. Ann Oncol 17 (Suppl 5): v13-v16, 2006.
17. O'Brien CP, Taylor SE, O'Leary JJ and Finn SP: Molecular testing in oncology: problems, pitfalls and progress. Lung Cancer 83: 309-315, 2014.
18. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006.
19. Takenaka T, Yoshino I, Kouso H, et al: Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 121: 895-900, 2007.
20. Tiseo M, Bordi P, Bortesi B, et al: A ERCC1/BRCA1 expression and gene polymorphisms as prognostic and predictive factors in advanced NSCLC treated with or without cisplatin. Br J Cancer 108: 1695-1703, 2013.
21. Rosell R, Cecere F, Santarpia M, Reguart N and Taron M: Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 6: 323-331, 2006.
22. Ota S, Ishii G, Goto K, et al: Immunohistochemical expression of BCRP and ERCC1 in biopsy specimen predicts survival in advanced non-small-cell lung cancer treated with cisplatin-based chemotherapy. Lung Cancer 64: 98-104, 2009.
23. Wachters FM, Wong LS, Timens W, Kampinga HH and Groen HJ: ERCC1, hRad51 and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 50: 211-219, 2005.
24. Filipits M and Pirker R: Predictive markers in the adjuvant therapy of non-small cell lung cancer. Lung Cancer 74: 355-363, 2011.
25. Filipits M, Haddad V, Schmid K, et al: Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 13: 3892-3898, 2007.
26. Voortman J, Goto A, Mendiboure J, et al: MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res 70: 8288-8298, 2010.
27. Filipits M, Pirker R, Dunant A, et al: Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 25: 2735-2740, 2007.
28. Pan H, Li L, Zuo CT, Mao NQ, Chen FL, Zhang W and Tang B J: Relationship between combined multigene detection and response to adjuvant chemotherapy in early-stage non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 30: 528-531, 2008.
29. Elbashir SM, Lendeckel W and Tuschl T: RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 15: 188-200, 2001.
30. Jiang J, Liang X, Zhou X, Huang R, Chu Z and Zhan Q: ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis. Mol Biol Rep 39: 6933-6942, 2012.
31. Tepeli E, Caner V, Buyukpinarbasili N, Cetin GO, Duzcan F, Elmas L and Bagci G: Expression of ERCC1 and its clinicopathological correlations in non-small cell lung cancer. Mol Biol Rep 39: 335-341, 2012.
32. Koc E, Caner V, Buyukpinarbasili N, Tepeli E, Turk NS, Ozan Cetin G and Bagci G: The determination of relationship between 'excision repair cross-complementing group 1' (ERCC1) gene T19007C and C8092A single nucleotide polymorphisms and clinicopathological parameters in non-small cell lung cancer. Mol Biol Rep 39: 375-380, 2012.
33. Yang Y and Xian L: The association between the ERCC1/2 polymorphisms and the clinical outcomes of the platinumbased chemotherapy in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Tumour Biol 35: 2905- 2921, 2014.
34. Friboulet L, Olaussen KA, Pignon JP, et al: ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. N Engl J Med 368: 1101-1110, 2013.
35. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007.
36. Altaha R, Liang X, Yu JJ and Reed E: Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 14: 959-970, 2004.
37. Chang IY, Kim MH, Kim HB, Lee DY, Kim SH, Kim HY and You HJ: Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 327: 225-233, 2005.